日本医薬品有効成分市場規模、シェア、競争環境、動向分析レポート :合成別(バイオテクノロジー及び合成))、力価別(伝統的APIとHPAPI)、メーカー別(キャプティブAPI及びマーチャントAPI)、タイプ別(ジェネリックAPI及び革新的API)、 薬物別(処方薬及び市販薬)、利用法別(臨床及び研究)、用途別(心臓血管疾患、腫瘍学、神経学、整形学、糖尿病、呼吸器学、消化器学、腎臓学、眼科、その他): 2024 年から 2032 年までの機会分析と業界予測
レポートID : ROJP0524086 | 発行日 : 2024年05月 | フォーマット : : :
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
List of Figures
Figure 1. Japan Active Pharmaceutical Ingredient Market, By Value, In USD Billion, FY2017-FY2031F
Figure 2. Japan Active Pharmaceutical Ingredient Market, By Volume, In Million Units, FY2017-FY2031F
Figure 3. Japan Active Pharmaceutical Ingredient Market Share (%), By Synthesis, FY2017-FY2031F
Figure 4. Japan Active Pharmaceutical Ingredient Market Share (%), By Potency, FY2017-FY2031F
Figure 5. Japan Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, FY2017-FY2031F
Figure 6. Japan Active Pharmaceutical Ingredient Market Share (%), By Type, FY2017-FY2031F
Figure 7. Japan Active Pharmaceutical Ingredient Market Share (%), By Drug, FY2017-FY2031F
Figure 8. Japan Active Pharmaceutical Ingredient Market Share (%), By Usage, FY2017-FY2031F
Figure 9. Japan Active Pharmaceutical Ingredient Market Share (%), By Application, FY2017-FY2031F
Figure 10. Japan Active Pharmaceutical Ingredient Market Share (%), By Region, FY2017-FY2031F
Figure 11. By Synthesis Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 12. By Potency Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 13. By Manufacturer Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 14. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 15. By Drug Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 16. By Usage Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 17. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2023
Figure 18. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2023